Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...

Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for ...

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Novo Nordisk late Thursday announced that it will advance subcutaneous (SC) and oral amycretin into Phase III development in ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug, amycretin, by early 2026. The drug mimics ...

The global diabetic retinopathy market has shown a consistent growth in recent years and is expected to continue for the coming several years. According to a report from Grand View Research said that ...

Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new ...